(Press-News.org) London, UK, Saturday 12 April 2014: Results from RESTORE , a phase III, multicentre, single-arm, open-label study presented today at the International Liver CongressTM 2014 showed that simeprevir 150 mg once-daily for 12 weeks in combination with peginterferon and ribavirin (followed by 12 or 36 weeks of peginterferon and ribavirin) was effective and well tolerated in hepatitis C virus (HCV) genotype 4-infected patients, consistent with previous observations in HCV genotype 1-infected patients.
Overall, 65.4% of patients achieved SVR12 (82.9% of treatment-naïve, 86.4% of prior-relapser, 60.0% of prior partial-responder and 40.0% of prior null-responder patients). The rapid virological response (RVR) rates in the IL28B CT and TT patient sub-groups were 65.5% and 62.2%, respectively, while 65.6% and 59.5% achieved SVR12, respectively. Among those patients with more severe liver fibrosis (METAVIR score F4), 62.1% and 46.7% achieved RVR and SVR12, respectively.
Response-guided therapy criteria used to identify patients eligible for a total treatment duration of 24 weeks were met by 88.6% and 90.9% of treatment-naïve and prior-relapser patients, respectively. Among them, 93.5% and 95.0%, respectively, achieved SVR12. No patients meeting response-guided therapy criteria experienced on-treatment failure, while three patients experienced viral relapse (treatment-naive, n=2; relapsers, n=1).
"HCV genotype 4 is a strain of virus which currently only has limited treatment options," said EASL's Secretary General Professor Markus Peck-Radosavljevic. "We therefore welcome these positive results for the simeprevir-based regimen."
Although HCV genotype 4 is mainly found in the Middle East, Egypt and Central Africa, it has recently spread in several Western countries, particularly in Europe, with rates of 10% to 24%.
Overall simeprevir was well tolerated; most adverse events (AEs) were grade 1 or 2. Serious AEs were infrequent (five patients [4.7%]; no deaths) and considered unrelated to simeprevir. Most frequent AEs (>30% of patients) included influenza-like illness, asthenia and fatigue.
In this phase III study conducted in France and Belgium, 107 patients with chronic HCV genotype 4 received simeprevir once daily with peginterferon and ribavirin for 12 weeks. Treatment-naïve and prior-relapser patients received response-guided therapy with peginterferon and ribavirin continued for up to 24 or 48 weeks. Prior partial responders and prior null responders continued to receive peginterferon and ribavirin for 48 weeks.
Out of a total patient population of 107 patients, 35 were treatment-naïve, 22 relapsers, 10 partial responders, and 40 null responders. The demographics of the patient population were as follows: 78.5% male; median age, 49 years; 28.0% Black; 28.8% METAVIR F4; 92.5% IL28B non-CC host genotype; and 42.5/23.6/33.9% HCV GT4a/4d/4other genotype.
Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB, with antiviral activity against HCV genotypes 1, 2, 4, 5 and 6, and approved in Japan, Canada, the United States and Russia for the treatment of chronic hepatitis C infection in combination with pegylated interferon and ribavirin in HCV genotype 1-infected patients with compensated liver disease, including cirrhosis. Taken as one capsule, once-daily, simeprevir works by blocking the protease enzyme that enables HCV to replicate in host cells.
Patients of Egyptian ancestry infected with Genotype 4 HCV achieve high virological response rates with sofosbuvir plus ribavirin
In a second study involving treatment-naive and treatment-experienced patients of Egyptian ancestry with chronic genotype 4 HCV infection, sofosbuvir plus ribavirin was shown to provide a simple, effective, and well-tolerated, interferon-free regimen.
After 12 weeks of treatment with sofosbuvir plus ribavirin, SVR12 rates were 79% (11/14) in treatment-naïve patients and 59% (10/17) in treatment-experienced patients. Extending treatment duration to 24 weeks resulted in higher SVR12 rates in both treatment-naïve and -experienced patients: 100% (14/14) and 87% (13/15) respectively.
Relapse accounted for all virological failures except in one treatment-naïve subject receiving 12 weeks treatment who had a partial response.
Most AEs were mild or moderate in severity and consistent with the known side effects of ribavirin.
Presenting these results, Professor Peck-Radosavljevic said "the current treatment for GT4 is sofosbuvir + pegylated interferon + ribavirin for 12 weeks which resulted in a 96% (27/28) SVR12 rate in the Phase 3 NEUTRINO trial.
"What makes the results from this new study with sofosbuvir so important is that it included those patients who were interferon-ineligible, -intolerant, and failures, where a significant unmet medical need exists", Professor Peck-Radosavljevic added.
In this study, patients, born in Egypt and of Egyptian ancestry, with chronic HCV GT4 infection were randomised 1:1, stratified by prior treatment status and cirrhosis status, to receive 12 or 24 weeks sofosbuvir (400 mg/day) + ribavirin (1000-1200 mg/day). Approximately 20% could have compensated cirrhosis.
Of the 60 patients enrolled, 28 were treatment-naïve and 32 treatment-experienced. 68% were male, 23% cirrhotic, and 17% had the IL28B CC host genotype.
Sofosbuvir is a nucleotide polymerase inhibitor with a high barrier to resistance that is taken as an oral, once-daily formulation. With activity against HCV genotypes 1-6, in-vitro activity of sofosbuvir against genotype 4a HCV has been shown to be similar to its activity against other HCV genotypes. With more than 3000 patients treated to date, sofosbuvir appears to be safe and well tolerated.
INFORMATION:
Disclaimer: the data referenced in this release is based on the submitted abstract. Final SVR results by baseline characteristics, including GT4 subtype, and resistance data will be presented at the International Liver Congress™ 2014.
Notes to Editors
About EASL
EASL is the leading European scientific society involved in promoting research and education in hepatology. EASL attracts the foremost hepatology experts and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.
EASL's main focus on education and research is delivered through numerous events and initiatives, including:
The International Liver CongressTM which is the main scientific and professional event in hepatology worldwide
Meetings including Monothematic and Special conferences, Post Graduate courses and other endorsed meetings that take place throughout the year
Clinical and Basic Schools of Hepatology, a series of events covering different aspects in the field of hepatology
Organisation of a Mentorship program and Masterclass to support young investigators starting out on their career path
Journal of Hepatology published monthly
Participation in a number of policy initiatives at European level
About The International Liver CongressTM 2014
The International Liver Congress™ 2014, the 49th annual meeting of the European Association for the study of the Liver, is being held at ExCel London from April 9 – 13, 2014. The congress annually attracts in excess of 9000 clinicians and scientists from around the world and provides an opportunity to hear the latest research, perspectives and treatments of liver disease from principal experts in the field.
For further information on the studies, or to request an interview, please do not hesitate to contact the EASL Press Office on:
Email: easlpressoffice@cohnwolfe.com
Helena Symeou +44 7976 562 430
Courtney Lock +44 7894 386 422
1. MORENO ET AL. ONCE-DAILY SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAÏVE OR TREATMENT-EXPERIENCED CHRONIC HCV GENOTYPE 4-INFECTED PATIENTS: SVR12 RESULTS OF A PHASE III TRIAL. ABSTRACT PRESENTED AT THE INTERNATIONAL LIVER CONGRESS™ 2014
2. ESTEBAN JI, SAULEDA S, QUER J. THE CHANGING EPIDEMIOLOGY OF HEPATITIS C VIRUS INFECTION IN EUROPE. J HEPATOL. 2008; 48 (1): 148-162.
3. RUANE, P.J ET AL. SOFOSBUVIR PLUS RIBAVIRIN, AN INTERFERON-FREE REGIMEN, IN THE TREATMENT OF TREATMENT-NAÏVE AND TREATMENT-EXPERIENCED PATIENTS WITH CHRONIC GENOTYPE 4 HCV INFECTION ABSTRACT PRESENTED AT THE INTERNATIONAL LIVER CONGRESS™ 2014
New data for HCV genotype 4 patients with simeprevir- and sofosbuvir-based regimens
2014-04-12
ELSE PRESS RELEASES FROM THIS DATE:
The Lancet Oncology: Challenges to effective cancer control in China, India, and Russia
2014-04-11
The Lancet Oncology today [Friday 11 April] publishes a major new Commission examining the challenges to effective cancer control in China, India, and Russia – which together experience 46% of all new cancers worldwide, and account for more than half (52%) of all cancer deaths globally. The Commission was led by Professor Paul Goss, of Harvard Medical School and Massachusetts General Hospital Cancer Center, USA, in collaboration with over 40 leading cancer experts from the regions studied, and across the world.
At the same time, the journal also publishes a three part ...
UAlberta researchers examine metabolism in defective cells
2014-04-11
UAlberta researchers are taking a closer look at how two metabolic pathways interact to increase the lifespan of cells with mitochondrial defects. Magnus Friis is the lead author of the study, which was published online on April 10 and will be published in the April 24 issue of Cell Reports.
Mitochondria produce energy for cells through oxidative metabolism, but the process produces toxic byproducts that can accumulate and cause defects in the cell's mitochondria. These defects, in turn, affect the cell's ability to generate energy and can potentially lead to cell death ...
Women with diabetes less likely to have a mammogram: Study
2014-04-11
TORONTO, April 11, 2014 – Women with diabetes are 14 per cent less likely to be screened for breast cancer compared to women without diabetes, according to a study by researchers at the Institute for Clinical Evaluative Sciences (ICES) and Women's College Hospital.
The study, published today in the journal Diabetic Medicine, is the first to examine the influence of socioeconomic status on the gap in mammogram screening among women with diabetes.
"Managing the demands of a chronic condition such as diabetes is challenging for many women, leaving other preventative actions, ...
BLOODHOUND team predicts the impact of the 1,000 mph supersonic car
2014-04-11
10th of April, 2014 (London). A new paper from the Swansea University, College of Engineering team working on the BLOODHOUND SSC (Supersonic car) project has been published on the aerodynamic characteristics of travelling at 1,000mph. Simulations have looked at how the car will cope with the supersonic rolling ground, rotating wheels and resulting shock waves in close proximity to the test surface at the record attempt site in Hakskeen Pan, South Africa. Where, in 2015, it will make high speed test runs of up to 800mph, with the full 1,000mph attempt scheduled for 2016.
...
Odds that global warming is due to natural factors: Slim to none
2014-04-11
An analysis of temperature data since 1500 all but rules out the possibility that global warming in the industrial era is just a natural fluctuation in the earth's climate, according to a new study by McGill University physics professor Shaun Lovejoy.
The study, published online April 6 in the journal Climate Dynamics, represents a new approach to the question of whether global warming in the industrial era has been caused largely by man-made emissions from the burning of fossil fuels. Rather than using complex computer models to estimate the effects of greenhouse-gas ...
Warming climate has consequences for Michigan's forests
2014-04-11
HOUGHTON, Mich., April 11, 2014 – In the last 100 years, Michigan has become warmer, with more rain coming through heavy downpours. Climate models suggest that the state will continue to warm and variability in precipitation patterns will increase, which will have consequences for the state's forests. A new U.S. Forest Service report describes the potential risks and opportunities of climate change for forests in the eastern Upper Peninsula and northern Lower Peninsula.
More than 30 scientists and forest managers contributed to "Michigan Forest Ecosystem Vulnerability ...
Berkeley graduate student brings extinct plants to life
2014-04-11
Jeff Benca is an admitted über-geek when it comes to prehistoric plants, so it was no surprise that, when he submitted a paper describing a new species of long-extinct lycopod for publication, he ditched the standard line drawing and insisted on a detailed and beautifully rendered color reconstruction of the plant. This piece earned the cover of March's centennial issue of the American Journal of Botany.
"Typically, when you see pictures of early land plants, they're not that sexy: there is a green forking stick and that's about it. We don't have many thorough reconstructions," ...
Facial selection technique for ads can increase buyers by 15 percent: INFORMS Marketing Science
2014-04-11
Merely changing the face of a model in an ad increases the number of potential purchasers by as much as 15% (8% on average), according to a study being published by the Institute for Operations Research and the Management Sciences (INFORMS).
"Just the Faces: Exploring the Effects of Facial Features in Print Advertising," appears in the Articles in Advance section of the INFORMS journal Marketing Science and will appear in print later this year. The research was conducted by Li Xiao, Assistant Professor of Marketing at Fudan University (China), and Min Ding, Smeal Professor ...
Sudden loss of consciousness
2014-04-11
According to a prospective study (the SPEED Study) presented by Yvonne Greve of Nuremberg Hospital et al. in Deutsches Ärzteblatt International (Dtsch Arztebl Int 2014; 111(12): 197), up to 3% of consultations at an emergency department concern a sudden loss of consciousness or near loss of consciousness.
In order to assess the frequency and prognostic significance of near syncope and syncope (the specialist terms for short-term near or complete loss of consciousness), the authors gathered data on 395 patients who presented to an emergency department with the typical ...
To be an organ donor, specific attitudes trump general support, study finds
2014-04-11
WASHINGTON -- Most Americans say they support the idea of organ donation, yet fewer than half of eligible donors ever register, national polls show. That may be because supporting a good cause doesn't mean people will take action. However, people are more likely to sign up if they have positive attitudes specifically about registering as a donor, according to research published by the American Psychological Association.
In a 2005 Gallup poll, 95 percent of Americans said they "support or strongly support" organ donation, yet only 40 percent of eligible donors have registered, ...